APO Research
Talk to an analyst

APO RESEARCH · REPORT

Macromolecular Single-target Angiogenesis Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Research

Macromolecular Single-target Angiogenesis Inhibitor Industry Research Report 2026

27 December 2025129 pages

Choose your research edition.

Industry ResearchMacromolecular Single-target Angiogenesis Inhibitor Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Macromolecular Single-target Angiogenesis Inhibitor Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Macromolecular Single-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Macromolecular Single-target Angiogenesis Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Macromolecular Single-target Angiogenesis Inhibitor Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Macromolecular Single-target Angiogenesis Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Macromolecular Single-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Macromolecular Single-target Angiogenesis Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Macromolecular Single-target Angiogenesis Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Macromolecular Single-target Angiogenesis Inhibitor include Amgen, Amneal Pharmaceuticals, Bayer, Celltrion Healthcare, Eli Lilly, Pfizer, Roche, Sanofi and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Macromolecular Single-target Angiogenesis Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Macromolecular Single-target Angiogenesis Inhibitor Market by Company

Amgen

Amneal Pharmaceuticals

Bayer

Celltrion Healthcare

Eli Lilly

Pfizer

Roche

Sanofi

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

Macromolecular Single-target Angiogenesis Inhibitor Segment by Type

Aflibercept

Bevacizumab

Ramucirumab

Other

Macromolecular Single-target Angiogenesis Inhibitor Segment by Application

Degenerative Eye Diseases

Cancer

Other

Macromolecular Single-target Angiogenesis Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Macromolecular Single-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Macromolecular Single-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Macromolecular Single-target Angiogenesis Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Macromolecular Single-target Angiogenesis Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Macromolecular Single-target Angiogenesis Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Macromolecular Single-target Angiogenesis Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Macromolecular Single-target Angiogenesis Inhibitor Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 8. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue of Manufacturers (2021-2026) Table 9. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Macromolecular Single-target Angiogenesis Inhibitor Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Macromolecular Single-target Angiogenesis Inhibitor Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Product Type & Application Table 14. Global Macromolecular Single-target Angiogenesis Inhibitor Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Macromolecular Single-target Angiogenesis Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amgen Company Information Table 19. Amgen Business Overview Table 20. Amgen Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Amgen Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 22. Amgen Recent Developments Table 23. Amneal Pharmaceuticals Company Information Table 24. Amneal Pharmaceuticals Business Overview Table 25. Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 27. Amneal Pharmaceuticals Recent Developments Table 28. Bayer Company Information Table 29. Bayer Business Overview Table 30. Bayer Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Bayer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 32. Bayer Recent Developments Table 33. Celltrion Healthcare Company Information Table 34. Celltrion Healthcare Business Overview Table 35. Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 37. Celltrion Healthcare Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 47. Pfizer Recent Developments Table 48. Roche Company Information Table 49. Roche Business Overview Table 50. Roche Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Roche Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 52. Roche Recent Developments Table 53. Sanofi Company Information Table 54. Sanofi Business Overview Table 55. Sanofi Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Sanofi Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 57. Sanofi Recent Developments Table 58. Jiangsu Hengrui Pharmaceuticals Company Information Table 59. Jiangsu Hengrui Pharmaceuticals Business Overview Table 60. Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 62. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 63. Qilu Pharma Company Information Table 64. Qilu Pharma Business Overview Table 65. Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 67. Qilu Pharma Recent Developments Table 68. SinoCellTech Company Information Table 69. SinoCellTech Business Overview Table 70. SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 72. SinoCellTech Recent Developments Table 73. Innovent Company Information Table 74. Innovent Business Overview Table 75. Innovent Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Innovent Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 77. Innovent Recent Developments Table 78. Chia Tai Tianqing Company Information Table 79. Chia Tai Tianqing Business Overview Table 80. Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 82. Chia Tai Tianqing Recent Developments Table 83. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (K Units) Table 85. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Region (2021-2026) Table 86. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2027-2032) & (K Units) Table 87. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Region (2027-2032) Table 88. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2021-2026) Table 90. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2027-2032) Table 92. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 94. North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 95. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 99. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 100. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 109. South America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 110. South America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 118. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2027-2032) & (K Units) Table 119. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026) Table 120. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2027-2032) Table 121. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2026) Table 124. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2027-2032) Table 125. Global Macromolecular Single-target Angiogenesis Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 126. Global Macromolecular Single-target Angiogenesis Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 127. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 128. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2027-2032) & (K Units) Table 129. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026) Table 130. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2027-2032) Table 131. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2026) Table 134. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2027-2032) Table 135. Global Macromolecular Single-target Angiogenesis Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 136. Global Macromolecular Single-target Angiogenesis Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Macromolecular Single-target Angiogenesis Inhibitor Distributors List Table 140. Macromolecular Single-target Angiogenesis Inhibitor Customers List Table 141. Macromolecular Single-target Angiogenesis Inhibitor Industry Trends Table 142. Macromolecular Single-target Angiogenesis Inhibitor Industry Drivers Table 143. Macromolecular Single-target Angiogenesis Inhibitor Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Macromolecular Single-target Angiogenesis Inhibitor Product Image Figure 5. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size (2021-2032) & (US$ Million) Figure 7. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (2021-2032) & (K Units) Figure 8. Global Macromolecular Single-target Angiogenesis Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 9. Aflibercept Product Image Figure 10. Bevacizumab Product Image Figure 11. Ramucirumab Product Image Figure 12. Other Product Image Figure 13. Degenerative Eye Diseases Product Image Figure 14. Cancer Product Image Figure 15. Other Product Image Figure 16. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Macromolecular Single-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region in 2025 Figure 22. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region in 2025 Figure 23. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country in 2025 Figure 24. North America Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 25. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2032) Figure 26. United States Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country in 2025 Figure 30. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 31. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2032) Figure 32. Germany Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country in 2025 Figure 43. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2032) Figure 45. China Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country in 2025 Figure 54. South America Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 55. South America Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2032) Figure 56. Brazil Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country in 2025 Figure 60. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2021-2032) Figure 62. Egypt Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2032) Figure 68. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2032) Figure 69. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021-2032) Figure 70. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2032) Figure 71. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2032) Figure 72. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021-2032) Figure 73. Macromolecular Single-target Angiogenesis Inhibitor Value Chain Figure 74. Macromolecular Single-target Angiogenesis Inhibitor Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Macromolecular Single-target Angiogenesis Inhibitor Industry Opportunities and Challenges

Scope & coverage.

Types
  • Aflibercept
  • Bevacizumab
  • Ramucirumab
  • Other
Applications
  • Degenerative Eye Diseases
  • Cancer
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals
  • Bayer
  • Celltrion Healthcare
  • Eli Lilly
  • Pfizer
  • Roche
  • Sanofi
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Size (2021-2032)
  4. 2.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales (2021-2032)
  5. 2.2.3 Global Macromolecular Single-target Angiogenesis Inhibitor Market Average Price (2021-2032)
  6. 2.3 Macromolecular Single-target Angiogenesis Inhibitor by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Aflibercept
  9. 2.3.3 Bevacizumab
  10. 2.3.4 Ramucirumab
  11. 2.3.5 Other
  12. 2.4 Macromolecular Single-target Angiogenesis Inhibitor by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Degenerative Eye Diseases
  15. 2.4.3 Cancer
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Macromolecular Single-target Angiogenesis Inhibitor Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Macromolecular Single-target Angiogenesis Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Product Type & Application
  8. 3.8 Global Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Established Date
  9. 3.9 Global Macromolecular Single-target Angiogenesis Inhibitor Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amgen
  2. 4.1.1 Amgen Company Information
  3. 4.1.2 Amgen Business Overview
  4. 4.1.3 Amgen Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amgen Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  6. 4.1.5 Amgen Recent Developments
  7. 4.2 Amneal Pharmaceuticals
  8. 4.2.1 Amneal Pharmaceuticals Company Information
  9. 4.2.2 Amneal Pharmaceuticals Business Overview
  10. 4.2.3 Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  12. 4.2.5 Amneal Pharmaceuticals Recent Developments
  13. 4.3 Bayer
  14. 4.3.1 Bayer Company Information
  15. 4.3.2 Bayer Business Overview
  16. 4.3.3 Bayer Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Bayer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  18. 4.3.5 Bayer Recent Developments
  19. 4.4 Celltrion Healthcare
  20. 4.4.1 Celltrion Healthcare Company Information
  21. 4.4.2 Celltrion Healthcare Business Overview
  22. 4.4.3 Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  24. 4.4.5 Celltrion Healthcare Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 Roche
  38. 4.7.1 Roche Company Information
  39. 4.7.2 Roche Business Overview
  40. 4.7.3 Roche Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Roche Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  42. 4.7.5 Roche Recent Developments
  43. 4.8 Sanofi
  44. 4.8.1 Sanofi Company Information
  45. 4.8.2 Sanofi Business Overview
  46. 4.8.3 Sanofi Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sanofi Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  48. 4.8.5 Sanofi Recent Developments
  49. 4.9 Jiangsu Hengrui Pharmaceuticals
  50. 4.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 4.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 4.9.3 Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  54. 4.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 4.10 Qilu Pharma
  56. 4.10.1 Qilu Pharma Company Information
  57. 4.10.2 Qilu Pharma Business Overview
  58. 4.10.3 Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  60. 4.10.5 Qilu Pharma Recent Developments
  61. 4.11 SinoCellTech
  62. 4.11.1 SinoCellTech Company Information
  63. 4.11.2 SinoCellTech Business Overview
  64. 4.11.3 SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  66. 4.11.5 SinoCellTech Recent Developments
  67. 4.12 Innovent
  68. 4.12.1 Innovent Company Information
  69. 4.12.2 Innovent Business Overview
  70. 4.12.3 Innovent Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Innovent Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  72. 4.12.5 Innovent Recent Developments
  73. 4.13 Chia Tai Tianqing
  74. 4.13.1 Chia Tai Tianqing Company Information
  75. 4.13.2 Chia Tai Tianqing Business Overview
  76. 4.13.3 Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  78. 4.13.5 Chia Tai Tianqing Recent Developments
5 Global Macromolecular Single-target Angiogenesis Inhibitor Market Scenario by Region
  1. 5.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2021-2032
  3. 5.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2021-2026
  4. 5.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2027-2032
  5. 5.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2021-2032
  6. 5.3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2021-2026
  7. 5.3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2027-2032
  8. 5.4 North America Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country
  9. 5.4.1 North America Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  11. 5.4.3 North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country
  16. 5.5.1 Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  18. 5.5.3 Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country
  41. 5.7.1 South America Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  43. 5.7.3 South America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021-2032)
  2. 6.1.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2032)
  4. 6.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2021-2032)
  5. 6.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Macromolecular Single-target Angiogenesis Inhibitor Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021-2032)
  2. 7.1.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2032)
  4. 7.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2021-2032)
  5. 7.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Macromolecular Single-target Angiogenesis Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Macromolecular Single-target Angiogenesis Inhibitor Value Chain Analysis
  2. 8.1.1 Macromolecular Single-target Angiogenesis Inhibitor Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Macromolecular Single-target Angiogenesis Inhibitor Production Mode & Process
  5. 8.2 Macromolecular Single-target Angiogenesis Inhibitor Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Macromolecular Single-target Angiogenesis Inhibitor Distributors
  8. 8.2.3 Macromolecular Single-target Angiogenesis Inhibitor Customers
9 Global Macromolecular Single-target Angiogenesis Inhibitor Analyzing Market Dynamics
  1. 9.1 Macromolecular Single-target Angiogenesis Inhibitor Industry Trends
  2. 9.2 Macromolecular Single-target Angiogenesis Inhibitor Industry Drivers
  3. 9.3 Macromolecular Single-target Angiogenesis Inhibitor Industry Opportunities and Challenges
  4. 9.4 Macromolecular Single-target Angiogenesis Inhibitor Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst